Skip to content
10-Q

Quarterly Report

PDL BioPharma, Inc.

0000882104-20-000181

← back to feed
Filed
Nov 13, 2020 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Oct 30, 2020 114.23M sh
Cash And Equivalents Q3 2020 · Sep 30, 2020 $125.74M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $168.98M
Shares Diluted Q3 2020 · Aug 31, 2020 113.89M sh
Shares Diluted Q3 2020 · Aug 31, 2020 118M sh
Shares Diluted Q3 2020 · Sep 30, 2019 112.99M sh
Shares Diluted Q3 2020 · Sep 30, 2019 119.97M sh
Stock Repurchased Q3 2020 · Aug 31, 2020 $39.37M
Stock Repurchased Q3 2020 · Sep 30, 2019 $75.89M
Capex Q3 2020 · Aug 31, 2020 $221K
Capex Q3 2020 · Sep 30, 2019 $504K
Stockholders Equity Q3 2020 · Aug 31, 2020 $425.21M
Stockholders Equity Q3 2020 · Dec 31, 2019 $593.2M
Stockholders Equity Q3 2020 · Mar 31, 2019 $693.78M
Stockholders Equity Q3 2020 · Dec 31, 2018 $729.78M
Eps Diluted Q3 2020 · Aug 31, 2020 $0.04
Eps Diluted Q3 2020 · Aug 31, 2020 −$0.66
Eps Diluted Q3 2020 · Sep 30, 2019 −$0.16
Eps Diluted Q3 2020 · Sep 30, 2019 −$0.13
Eps Basic Q3 2020 · Aug 31, 2020 $0.04
Eps Basic Q3 2020 · Aug 31, 2020 −$0.66
Eps Basic Q3 2020 · Sep 30, 2019 −$0.16
Eps Basic Q3 2020 · Sep 30, 2019 −$0.13
Sga Expense Q3 2020 · Aug 31, 2020 $7.22M
Sga Expense Q3 2020 · Aug 31, 2020 $29.7M
Sga Expense restated Q3 2020 · Sep 30, 2019 $10.06M
Sga Expense restated Q3 2020 · Sep 30, 2019 $27.07M
Rd Expense Q3 2020 · Aug 31, 2020 $1.05M
Rd Expense Q3 2020 · Aug 31, 2020 $4.37M
Rd Expense Q3 2020 · Sep 30, 2019 $4.31M
Rd Expense restated Q3 2020 · Sep 30, 2019 $6.11M
Net Income Q3 2020 · Aug 31, 2020 $4.4M
Net Income Q3 2020 · Aug 31, 2020 −$77.3M
Net Income Q3 2020 · Sep 30, 2019 −$17.78M
Net Income Q3 2020 · Sep 30, 2019 −$15.52M
Operating Income Q3 2020 · Aug 31, 2020 −$8.73M
Operating Income Q3 2020 · Aug 31, 2020 −$54.25M
Operating Income restated Q3 2020 · Sep 30, 2019 −$12.97M
Operating Income restated Q3 2020 · Sep 30, 2019 −$30.45M
Cost Of Revenue Q3 2020 · Aug 31, 2020 $1.13M
Cost Of Revenue Q3 2020 · Aug 31, 2020 $6.63M
Cost Of Revenue restated Q3 2020 · Sep 30, 2019 $4.77M
Cost Of Revenue restated Q3 2020 · Sep 30, 2019 $13.49M
Stock Issued Q3 2020 · Mar 31, 2020 13.4M sh
Current Liabilities Q3 2020 · Dec 31, 2019 $45.69M
Total Liabilities Q3 2020 · Dec 31, 2019 $123.93M
Current Assets Q3 2020 · Dec 31, 2019 $313.9M
Total Assets Q3 2020 · Dec 31, 2019 $717.21M